Background: The recent approval of anti-PD1 or PDL1 immunotherapy based on promising clinical trial results ushers in the accelerated adoption of pertinent companion diagnostics to make available the relevant therapy to cancer patients. The Lung Center of the Philippines established a routine immunohistochemistry-based diagnostic for PDL1 in collaboration with pharmaceutical companies to address the existing gap in diagnostic information that may have therapeutic implications in terms of who and to what extent, this subset of population may benefit from this new targeted therapy. This study aims to report the PDL1 profile of Filipino lung adenocarcinoma patients and evaluate its possible correlation with EGFR mutation. Method: Tumor block samples from 345 Filipino lung adenocarcinoma patients were processed for PDL1 testing using the Ventana PDL1 Assay. Samples with positive results were subjected to Cobas EGFR mutation testing. Result: One hundred forty-two samples (i.e., 41.2%) were positive for the PDL1 markers. Majority of samples tested were males (i.e., 62-65% males vs. 35-38% females) with ages ranging from 64-66 years for both males and females. From a subset of eleven PDL1 positive samples, only three showed positive EGFR mutations (i.e., 27.3%) with two, showing L858R mutation and one T790M mutation. Conclusion: Moderate presence of the PDL1 markers were shown by Filipino lung adenocarcinoma patients suggesting that a moderate population could potentially benefit from anti-PD1 or PDL1 immunotherapy. Meanwhile, the low presence of EGFR mutation detected from the subset of PDL1 positive samples suggest a possibly mutually exclusive pattern for these biomarkers consistent with those reported in other studies. Albeit preliminary, co-EGFR testing could provide rationalization of clinical response and an alternative therapeutic targeting for this subset of patients.
P3.09-02 Utilization of Laboratory Developed Tests for PD-L1 Evaluation is Dependent on Tumor Type A. Chander, 1 B. Beshai, 1 K. Attwood, 2 A. Omilian, 3 J. Qiu 1 1 Department of Pathology, Roswell Park Comprehensive Cancer Center, Buffalo, NY/US, 2 Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY/US, 3 Department of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, NY/US Background: PD-L1 expression level evaluated by immunohistochemistry plays an important role in immunotherapy for many malignancies including non-small cell carcinoma of the lung (NSCLC), adenocarcinoma of the gastroesophageal junction/stomach (GEJ-G), melanoma and etc. With the growing number of indications for the use of PD-L1 immunotherapy, it has become impracticable for laboratories to adopt and maintain the various FDA approved assays for different tumor types. Harmonization to a standard assay would alleviate the current challenges and allow testing to be uniform among laboratories. The primary objective of this study was to determine if laboratory developed tests (LDTs) utilizing available antibodies are concordant with the FDA approved assays in NSCLC, melanoma and GEJ-G, and can therefore serve as alternatives for FDA approved assays. Method: Multiple tissue microarray slides containing NSCLC (714 cases), melanoma (87 cases) and GEJ-G (194 cases) were stained for PD-L1 with the 22C3 pharmDx Kit, the 28-8 pharmDx Kit, and/or three LDTs (clones 22C3, 28-8 and E1L3N). PD-L1 expression on tumor cells was scored for NSCLC and malignant melanoma, whereas expression on tumor cells and immune cells was scored for GEJ-G. All TMA slides were digitally scanned and independently evaluated by three board certified pathologists (JQ, AC, and BB) who were blinded to staining conditions. Raw scores were converted to a composite score based on the range of raw scores. Composite scores were compared for level of agreement utilizing a Kappa score and interclass correlation coefficients displayed on Bland-Altman plots. Result: For NSCLC, the two FDA approved assays have a high level of concordance (Kappa 0.88, 95% CI 0.85-0.90) and the two LDTs (22C3 and E1L3N) also have high level of concordance (Kappa 0.82, 95% CI 0.78-0.85); however, concordance between two FDA approved assays and the two LDTs was low. For gastric adenocarcinoma, the 22C3 FDA approved assay and 22C3 LDT has a high level of concordance (Kappa 0.90, 95% CI 0.86-0.94), but the E1L3N LDT has a low level of concordance with both the 22C3 FDA approved assay and the 22C3 LDT. For malignant melanoma, there was low concordance among two FDA approved assays and two LDTs (28-8 and E1L3N). Conclusion: These results suggest that although LDTs can be used for evaluating PD-L1 in tumor, the utilization of LDT is tumor type dependent. One single LDT may not be sufficient to serve as appropriate alternative for the FDA approved assays on different types of tumor. Keywords: PD-L1, laboratory developed tests Background: Lung cancer is the leading cause of cancer death. Better understanding of factors and pathways involved in lung cancer is needed to improve diagnose and treatment strategies. Recent studies have provided insights into the possible correlation between intestinal dysbiosis and cancer development. Although the immunological relationship between gut and lung had been suggested by many researches, however, to date, no study had investigated the characterization of gut microbiome in treatment naïve lung cancer patients, whether it is distinct from that of health individuals and contribute to the onset and development of lung cancer remain unclear. Method: In this study, we investigated whether gut microbiome of lung cancer patients (LC, n¼28) is altered compare with that of matched healthy individuals (HC, n¼19) by high throughout sequencing of the V3-V4 regions of 16S rDNA in their fecal samples. We also identified microbiota signatures specific for different histological types of lung cancer, including SSC, ADC, and SCLC. Result: The gut microbiome of lung cancer patients is characterized by decreased relative abundance of Prevotella, and increased bacteria groups such as Actinomyces, and Streptococcus, etc. We also detected an mild structural shift in gut microbiome between ADC and SCLC patients. Conclusion: Our results showed that the gut microbiome of lung cancer patients altered significantly compared with healthy individuals. However, the association between microbial dysbiosis and lung cancer is not clearly understood, future studies involving larger cohorts and metagenomics, or metabolomics, may elucidate the correlations between gut microbiota and lung cancer development. Keywords: gut microbiome, dysbiosis, lung cancer
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